Clinical Trial Update: IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating autologous CD133+ stem cell therapy in patients undergoing coronary artery bypass grafting has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Myocardial Infarction

Drugs mentioned

• Autologous CD133+ stem cell therapy

Snippet

Sponsor: University Health Network, Toronto | Conditions: Heart Failure, Heart Attack | Phase 2 | Status: COMPLETED